Results 1 to 10 of about 2,500,398 (351)

Updated Clinical Classification of Pulmonary Hypertension [PDF]

Journal of the American College of Cardiology, 2013
In 1998, a clinical classification of pulmonary hypertension (PH) was established, categorizing PH into groups which share similar pathological and hemodynamic characteristics and therapeutic approaches.
Simonneau, Gerald, Gatzoulis, Michael A., Adatia, Ian, Celermajer, David, Denton, Chris, Ghofrani, Ardeschir, Gomez Sanchez, Miguel Angel, Krishna Kumar, R., Landzberg, Michael, Machado, Roberto F., Olschewski, Horst, Robbins, Ivan M., Souza, Rogiero   +12 more
core   +5 more sources

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

European Heart Journal, 2022
Guidelines summarize and evaluate available evidence, with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition.
M. Humbert, G. Kovacs, M. Hoeper, Roberto Badagliacca, R. Berger, M. Brida, J. Carlsen, A. Coats, P. Escribano‐Subias, P. Ferrari, D. S. Ferreira, H. Ghofrani, G. Giannakoulas, D. Kiely, E. Mayer, G. Meszaros, Blin Nagavci, K. Olsson, J. Pepke-Zaba, J. Quint, G. Rådegran, G. Simonneau, O. Sitbon, T. Tonia, M. Toshner, J. Vachiéry, A. Vonk Noordegraaf, M. Delcroix, S. Rosenkranz   +28 more
semanticscholar   +2 more sources

Incidence and outcomes of pulmonary hypertension in the Ireland

BMJ Open Respiratory Research, 2022
Introduction Pulmonary hypertension (PH) is a progressive disease of the pulmonary vasculature, which is characterised by premature morbidity and mortality.
Sarah Cullivan, Sean Gaine, Brian McCullagh, Denise Lennon, Salima Meghani, Caitriona Minnock   +5 more
doaj   +1 more source

Pathophysiology and new advances in pulmonary hypertension

BMJ Medicine, 2023
Pulmonary hypertension is a progressive and often fatal cardiopulmonary condition characterised by increased pulmonary arterial pressure, structural changes in the pulmonary circulation, and the formation of vaso-occlusive lesions.
S. Bousseau, R. Sobrano Fais, S. Gu, A. Frump, T. Lahm   +4 more
semanticscholar   +1 more source

Characteristics of chronic thromboembolic pulmonary hypertension in Ireland

Pulmonary Circulation, 2021
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and under‐recognised complication of acute pulmonary embolism. Information regarding the characteristics of CTEPH in Ireland is limited, and the aim of this retrospective cohort study was to
Sarah Cullivan, Ciara McCormack, Marissa O’Callaghan, Barry Kevane, Fionnuala NiAinle, Brian McCullagh, Sean P. Gaine   +6 more
doaj   +1 more source

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study

Respiratory Research, 2023
Background Epoprostenol AS (Veletri®), a thermostable epoprostenol formulation, provides better drug stability and improved clinical use compared to previous epoprostenol formulations. This study aims to expand clinical experience in the use of Veletri®,
Julia Degering, Benjamin Egenlauf, Satenik Harutyunova, Nicola Benjamin, Amina Salkić, Panagiota Xanthouli, Christina A. Eichstaedt, Rebekka Seeger, Olivier Sitbon, Ekkehard Grünig   +9 more
doaj   +1 more source

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.

New England Journal of Medicine, 2021
BACKGROUND No therapies are currently approved for the treatment of pulmonary hypertension in patients with interstitial lung disease. The safety and efficacy of inhaled treprostinil for patients with this condition are unclear.
A. Waxman, R. Restrepo-Jaramillo, T. Thenappan, A. Ravichandran, P. Engel, A. Bajwa, R. Allen, J. Feldman, Rahul G Argula, Peter Smith, K. Rollins, C. Deng, L. Peterson, H. Bell, V. Tapson, S. Nathan   +15 more
semanticscholar   +1 more source

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up

Respiratory Research, 2020
Background The objective of this study was to analyze prognostic factors and risk stratification in patients with pulmonary arterial hypertension (PAH) and comorbidities.
Panagiota Xanthouli, Maria Koegler, Alberto M. Marra, Nicola Benjamin, Lukas Fischer, Christina A. Eichstaedt, Satenik Harutyunova, Christian Nagel, Ekkehard Grünig, Benjamin Egenlauf   +9 more
doaj   +1 more source

Sotatercept for the Treatment of Pulmonary Arterial Hypertension.

New England Journal of Medicine, 2021
BACKGROUND Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes.
M. Humbert, V. McLaughlin, J. Gibbs, M. Gomberg-Maitland, M. Hoeper, I. Preston, R. Souza, A. Waxman, Pilar Escribano Subías, J. Feldman, G. Meyer, D. Montani, K. Olsson, S. Manimaran, J. Barnes, P. Linde, J. de Oliveira Pena, D. Badesch   +17 more
semanticscholar   +1 more source

Prognostic meaning of right ventricular function and output reserve in patients with systemic sclerosis

Arthritis Research & Therapy, 2022
Background The objective of this study was to investigate the prognostic impact of right ventricular (RV) function at rest and during exercise in patients with systemic sclerosis (SSc) presenting for a screening for pulmonary hypertension (PH).
Panagiota Xanthouli, Julia Miazgowski, Nicola Benjamin, Ojan Gordjani, Benjamin Egenlauf, Satenik Harutyunova, Rebekka Seeger, Alberto M. Marra, Norbert Blank, Hanns-Martin Lorenz, Ekkehard Grünig, Christina A. Eichstaedt   +11 more
doaj   +1 more source